结核分枝杆菌乙胺丁醇耐药机制的研究进展

doi:10.16288/j.yczz.16-111

遗传 ›› 2016, Vol. 38 ›› Issue (10): 910-917.doi: 10.16288/j.yczz.16-111

结核分枝杆菌乙胺丁醇耐药机制的研究进展

王婷, 焦伟伟, 申阿东

首都医科大学附属北京儿童医院,北京市儿科研究所,儿童呼吸道感染性疾病研究北京市重点实验室,教育部儿科重大疾病研究重点实验室,北京 100045

收稿日期:2016-04-01 修回日期:2016-07-28 出版日期:2016-10-20 发布日期:2016-10-20
作者简介:申阿东,硕士,研究员,博士生导师,研究方向：儿童呼吸感染性疾病。
基金资助:
国家自然科学基金项目(编号：81271889,30901632)资助

Progress on mechanism of ethambutol resistance in Mycobacterium Tuberculosis

Ting Wang, Weiwei Jiao, Adong Shen

Key Laboratory of Major Diseases in Children and National Key Discipline of Pediatrics (Capital Medical University), Ministry of Education, Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China

Received:2016-04-01 Revised:2016-07-28 Online:2016-10-20 Published:2016-10-20
Supported by:
[Supported by the National Natural Science Foundation of China (Nos; 81271889,30901632)]

摘要/Abstract

摘要： 耐多药结核病的出现和流行对结核病的防控造成了严重威胁。乙胺丁醇(Ethambutol, EMB)是一线抗结核药物,常与异烟肼、利福平等联合应用,还可用于耐药结核病的治疗。但近年来EMB耐药形势严峻,我国复治结核病患者中EMB耐药率已达17.2%,并呈上升趋势;耐多药结核病患者中,EMB耐药率约为51.3%~66.7%,情况不容乐观。明确EMB耐药的产生机制对于有效防控EMB耐药率的上升、充分发挥EMB的作用十分重要,因此本文对结核分枝杆菌EMB的耐药现状、EMB的作用机制及其耐药产生机制方面的研究进展进行了综述。

关键词: 结核分枝杆菌, 乙胺丁醇, 耐药

Abstract: The occurance and prevalence of multidrug-resistant tuberculosis poses a serious threat to the global tuberculosis control. Ethambutol (EMB) is one of the first-line anti-tuberculosis drugs, which is usually used in combination with isoniazid and rifampicin for treating pan-sensitive tuberculosis, and it can also be used in drug-resistant tuberculosis. However, the situation of EMB resistance is alarmingly high, especially in multi-drug resistant tuberculosis. In China, EMB resistance rate in the previously treated cases was up to 17.2% and showed an increased tendency. What was worse, 51.3%-66.7% of multidrug-resistant tuberculosis cases were resistant to EMB. Thus, it is important to understand the drug resistance mechanism of EMB, which will help to slow down the drug resistance rate of EMB. In this review, we focus on the current status of EMB resistance, the effects of EMB and the mechanisms of EMB resistance in Mycobacterium tuberculosis.

Key words: Mycobacterium tuberculosis, ethambutol, drug resistance

王婷, 焦伟伟, 申阿东. 结核分枝杆菌乙胺丁醇耐药机制的研究进展[J]. 遗传, 2016, 38(10): 910-917.

Ting Wang, Weiwei Jiao, Adong Shen. Progress on mechanism of ethambutol resistance in Mycobacterium Tuberculosis[J]. Hereditas(Beijing), 2016, 38(10): 910-917.

参考文献

[1] World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization, 2015.
[2] He GX, Zhao YL, Jiang GL, Liu YH, Xia H, Wang SF, Wang LX, Borgdorff MW, van der Werf MJ, van den Hof S. Prevalence of tuberculosis drug resistance in 10 provinces of China. BMC Infect Dis , 2008, 8(1): 166.
[3] Zhao YL, Xu SF, Wang LX, Chin DP, Wang SF, Jiang GL, Xia H, Zhou Y, Li Q, Ou XC, Pang Y, Song YY, Zhao B, Zhang HT, He GX, Guo J, Wang Y. National survey of drug-resistant tuberculosis in China. N Engl J Med , 2012, 366(23): 2161-2170.
[4] Gonzalo X, Hutchison DC, Drobniewski FA, Pimkina E, Davidaviciene E. Multidrug-resistant tuberculosis in the United Kingdom and Lithuania. Int J Tuberc Lung Dis , 2014, 18(6): 663-665.
[5] Zhang ZJ, Wang YG, Pang Y, Kam KM. Ethambutol resistance as determined by broth dilution method correlates better than sequencing results with embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol , 2014, 52(2): 638-641.
[6] Chen QY, Pang Y, Liang QF, Lin SF, Wang YF, Lin J, Zhao Y, Wei SZ, Zheng JF, Zheng SH. Molecular characteristics of MDR Mycobacterium tuberculosis strains isolated in Fujian, China. Tuberculosis , 2014, 94(2): 159-161.
[7] Shi DW, Li L, Zhao YL, Jia Q, Li H, Coulter C, Jin Q, Zhu GF. Characteristics of embB mutations in multidrug- resistant Mycobacterium tuberculosis isolates in Henan, China. J Antimicrob Chemother , 2011, 66(10): 2240-2247.
[8] Chatterjee D. The mycobacterial cell wall: structure, biosynthesis and sites of drug action. Curr Opin Chem Biol , 1997, 1(4): 579-588.
[9] Jankute M, Grover S, Rana AK, Besra GS. Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets. Future Microbiol , 2012, 7(1): 129-147.
[10] Srivastava S, Ayyagari A, Dhole TN, Nyati KK, Dwivedi SK. emb nucleotide polymorphisms and the role of embB 306 mutations in Mycobacterium tuberculosis resistance to ethambutol. Int J Med Microbiol , 2009, 299(4): 269-280.
[11] Ramaswamy SV, Amin AG, Göksel S, Stager CE, Dou SJ, El Sahly H, Moghazeh SL, Kreiswirth BN, Musser JM. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother , 2000, 44(2): 326-336.
[12] Ahmad S, Jaber AA, Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and-resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis , 2007, 87(2): 123-129.
[13] Mokrousov I, Otten T, Vyshnevskiy B, Narvskaya O. Detection of embB306 mutations in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis from northwestern Russia: implications for genotypic resistance testing. J Clin Microbiol , 2002, 40(10): 3810-3813.
[14] Hazbón MH, Bobadilla del Valle M, Guerrero MI, Varma-Basil M, Filliol I, Cavatore M, Colangeli R, Safi H, Billman-Jacobe H, Lavender C, Fyfe J, García-García L, Davidow A, Brimacombe M, León CI, Porras T, Bose M, Chaves F, Eisenach KD, Sifuentes-Osornio J, Ponce de León A, Cave MD, Alland D. Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS 6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother , 2005, 49(9): 3794-3802.
[15] Madison B, Robinson-Dunn B, George I, Gross W, Lipman H, Metchock B, Sloutsky A, Washabaugh G, Mazurek G, Ridderhof J. Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol , 2002, 40(11): 3976-3979.
[16] Safi H, Sayers B, Hazbón MH, Alland D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother , 2008, 52(6): 2027-203

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

结核分枝杆菌乙胺丁醇耐药机制的研究进展

Progress on mechanism of ethambutol resistance in Mycobacterium Tuberculosis

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	吴丽雯, 曾洁, 薛云新, 赵西林. 细菌Cpx信号转导系统的功能及调控机制研究进展[J]. 遗传, 2021, 43(8): 747-757.
[2]	郑宏源, 闫琳, 杨超, 武雅蓉, 秦婧靓, 郝彤宇, 杨大进, 郭云昌, 裴晓燕, 赵彤言, 崔玉军. 溶藻弧菌群体基因组学研究[J]. 遗传, 2021, 43(4): 350-361.
[3]	陈湖星, 徐蕾, 李静, 郭政, 敖露. 基于结直肠癌细胞系MIC₅₀相关基因对的基础耐药评分模型构建[J]. 遗传, 2020, 42(6): 577-585.
[4]	邓雯文, 李才武, 赵思越, 李仁贵, 何永果, 吴代福, 杨盛智, 黄炎, 张和民, 邹立扣. 大熊猫源致病大肠杆菌CCHTP全基因组测序及耐药和毒力基因分析[J]. 遗传, 2019, 41(12): 1138-1147.
[5]	张沥元, 黄芙静, 许峻旗, 龚真, 谢建平. 结核分枝杆菌酸抗性基因及其调控网络[J]. 遗传, 2018, 40(7): 546-560.
[6]	祝力骋,卢俊婉,王建,许腾,徐娟华. 肺炎克雷伯菌bla_CARB-2基因的分布及结构分析[J]. 遗传, 2018, 40(7): 593-600.
[7]	易灵娴,刘艺云,吴仁杰,梁梓森,刘健华. 质粒介导的黏菌素耐药基因mcr-1研究进展[J]. 遗传, 2017, 39(2): 110-126.
[8]	杨盛智, 吴国艳, 龙梅, 邓雯文, 王红宁, 邹立扣. 鸡蛋生产链中沙门氏菌对抗生素及消毒剂的耐药性研究[J]. 遗传, 2016, 38(10): 948-956.
[9]	高薇1, 史伟1, 陈长会2, 文德年3, 田进2, 姚开虎1. 临床肺炎链球菌常见序列型青霉素耐药性的流行病学研究[J]. 遗传, 2016, 38(10): 940-947.
[10]	刘洋, 王邦兴, 刘志永, 韩轶, 谭耀驹, 李昕洁, 刘健雄, 谭守勇, 张天宇. 非一线抗结核药物耐药机制及耐药性诊断研究进展[J]. 遗传, 2016, 38(10): 928-939.
[11]	张玉娇, 李晓静, 米凯霞. 结核分枝杆菌耐氟喹诺酮类药物的分子机制研究进展[J]. 遗传, 2016, 38(10): 918-927.
[12]	马丽娜, 米宏霏, 薛云新, 王岱, 赵西林. ROS在细菌耐药及抗生素杀菌中的作用机制[J]. 遗传, 2016, 38(10): 902-909.
[13]	陈昱帆, 刘诗胤, 梁志彬, 吕明发, 周佳暖, 张炼辉. 群体感应与微生物耐药性[J]. 遗传, 2016, 38(10): 881-893.
[14]	张刚, 冯婕. 细菌固有耐药的研究进展[J]. 遗传, 2016, 38(10): 872-880.
[15]	谢龙祥, 于召箫, 郭思瑶, 李萍, AbualgasimElgailiAbdalla, 谢建平. 表观遗传和蛋白质翻译后修饰在细菌耐药中的作用[J]. 遗传, 2015, 37(8): 793-800.